Corporate PresentationDEC 2016

1

Executive Summary

• Clinical stage medical technology company

• Targeting Glaucoma, a major market with high potential for growth

• Innovative biocompatible STAR® material offers unique potential for treating glaucoma thru bio-integration

• MINIject™ designed to be best in class MIGSdevice

• Strong, experienced management team, board of Directors and Scientific Advisors

2

STAR® material

MINIject™

History

Patent filed: ‘Novel Porous Biomaterials’

iStar Medical Founded

STARflo™ Glaucoma Drainage Device; First in Human

Series A Financing

Initiated First Multicentre Clinical Trial for STARflo™

Strengthened Management Team & Board

Series B Financing

2003

2010

2011

2013

2014

2016

2015

3

Board of Directors and Management Team

Michel Lussier, Chairman of the Board30 years of experience in Medical Technology Chairman of Celyad, founder of Medpole, a European distribution incubator for medical device start-up companies and co-founder of Cardio3 BiosciencesFormerly a senior executive with Medtronic and Volcano

Philippe DegiveRepresentative of Société Régionale d'Investissement de Wallonie (“SRIW”)Formerly with BNP Paribas FortisCurrent and past board memberships include Bone Therapeutics, PrometheraBiosciences, Euroscreen, Cardio Life Research

Max MaginnessPresident and co-founder, Healionics CorporationFormerly with Siemens Medical, ATL (now Philips Ultrasound) and subsidiaries of CIBA-Geigy managing multiple new product development and technology transfer projects

Marc Nolet de Brauwere30 years of industry experience and a successful track record in building and leading companies in ophthalmologyCurrently board membership include Bone Therapeutics, Cardiatis, Mymicroinvest, Endo Tools Therapeutics, Biotech Coaching and AliaxisCEO of PhysIOL,, an innovative med-tech company active in the conception, manufacturing and sales of cutting-edge intraocular lenses (IOLs)

Katya SmirnyaginaPartner, Capricorn Health-Tech Venture FundFormerly with Alta PartnersCurrent and past board memberships include Adocia, Confo Therapeutics, NexstimOy, Ablynx, Cerenis Therapeutics, Innate Pharma and Kiadis Pharma

Marty Wax, MDChief Medical Officer and Executive VP of R&D at PanOptica, Inc., Formerly Vice-President and Head of Discovery Research and Pre-Clinical Sciences at Alcon LaboratoriesClinical Professor of Ophthalmology and Visual Sciences at Rutgers Medical School in Newark, N.J.

Michel Vanbrabant, CEO20 years of experience in Medical TechnologyHeld several international positions at leading MedTech companies including Guidant Inc. (now Boston Scientific) and St.Jude MedicalExperience in several start-up organisations with a focus on go-to market strategy and implementation

Zubair Hussain, Regulatory & Clinical Affairs20+ years experience in Regulatory, Quality, Compliance and Clinical Affairs for Pharmaceutical and Medical Device companies.Formerly with Pfizer, Alcon, IpsenExperience in Global Regulatory, both strategic and operational, Clinical Affairs, including in Vision care

Dan Scherrer, Operations20+ years experience in Operations and Supply Chain Management for Medical Device, Food and Electronics.Formerly with DePuy Spine (JNJ), Synthes, BiwiExperience in overall operations from Product Development to Supply Chain

Pierre Geens, R&D10 years of experience in manufacturing, engineering, and international quality assurance rolesFormerly with GSK Pharmaceuticals, Baxter Healthcare, GSK VaccinesExperience in manufacturing, validation, R&D quality system, quality assurance and market access

Cecile Roy, Manufacturing5 years of research experience with bio-polymeric products for drug delivery applications Co-inventor of the STARflo MINIject deviceMaster’s Degree in Civil Engineering and a Ph.D. in Engineering Sciences from the UniversitéCatholique de Louvain

4

Boa

rd o

f Dire

ctor

s

Man

agem

ent

Team

Glaucoma: Progressive, sight-threatening disease

80 million suffering

today90 million in

20201

Chronic progressive

diseaseDevastating

impact on patient’s

vision

Current therapeutic options aim at lowering intraocular

pressure (IOP)

2nd cause of blindness

after macular degeneration

worldwide2

1 Glaucoma Research Foundation

2. WHO/NMH/PBD/12.01 – Global data on visual impairments 2010 & Glaucoma Devices: Progress On Multiple Fronts, Elsevier Business Intelligence, April 2013

Fastest growing segment

(MIGS)

>€4.0 B care costsMeds

Laser & surgery

Drainage Devices

5

Intended Benefits

iSTAR Technology:A Unique Drainage Implant for Glaucoma

Medical-grade silicone with micro-porous geometry

Soft, flexible, biocompatible

STAR Biomaterial

Bleb-free surgery

Acts on the natural uveoscleral drainage pathway

Anti-fibrotic biomaterialAdjunct of antimetabolites (mitomycin) not required

Living tissue integration without blockage

Sustained efficacy

Fewer complications

Less post-op patient management

Better drainage

Low scarring and infection

Supra-choroidal Placement

6

iSTAR Product Pipeline

Feasibility study complete

Multi-center Study in progress

Product Development complete

First in Human H2-2016

STARflo MINIject

STAR Biomaterial Proof of Concept(Ab Externo Version)

MIGS(Ab Interno Version)

7

The STARflo Technology:Anti-fibrotic STAR® Biomaterial

8

STAR® Biomaterial developed at the University of Washington, Seattle, USA

PoreThroat

Medical grade silicone with precision-pore geometry

Soft, flexible, tissue-friendly

Rabbit Study: Suprachoroidal Placement – 6m Follow Up

IrisCornea

Sclera

Choroid

STARflo

Retina

No Encapsulation

observed as shown by the absence of surrounding fibrous capsule or continuous macrophage or fibroblast layer

Exceptional Biointegration

of the device with surrounding tissue colonizing the porous structure while preserving in vivo drainage efficacy

9

iSTAR Product PipelineProof of Concept (Ab Externo version)

STARflo

10

Inserted through an incisional surgical

procedure by Glaucoma surgeons

11

Targeting suprachoroidal space, avoiding bleb formation,

minimising post-operative patient management

• Design objective: a high-performing, safe MIGS device resulting in significant

and sustained intraocular pressure (IOP) reduction

• Developed in close collaboration with world leading scientific and clinical advisors

• Delivery through a small corneal incision of 2.2 mm ; can be performed by cataract and glaucoma surgeons

iSTAR Product PipelineMIGS (Micro-Invasive): MINIject

Milestones

Series B Financing

1st Patient in MINIject trial

Results from STARflo Multi-centre Study

CE-Marking MINIject

IDE MINIjectFiling

April 2016

H2 2016

Q2 2017

2018

2018

12

✔